Alto Neuroscience, Inc.
ANRO · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $59,558 | $58,426 | $114,153 |
| - Cash | $137,816 | $147,585 | $160,754 | $168,229 |
| + Debt | $26,404 | $4,214 | $26,438 | $16,944 |
| Enterprise Value | – | -$83,813 | -$75,890 | -$37,132 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$164 | -$100 | $0 | -$170 |
| % Margin | – | – | – | – |
| EBITDA | -$13,367 | -$16,960 | -$14,400 | -$14,698 |
| % Margin | – | – | – | – |
| Net Income | -$14,181 | -$17,706 | -$15,169 | -$15,201 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.52 | -0.65 | -0.56 | -0.56 |
| % Growth | 20% | -16.1% | 0% | – |
| Operating Cash Flow | -$9,918 | -$13,779 | -$16,556 | -$13,021 |
| Capital Expenditures | $0 | $0 | -$24 | -$506 |
| Free Cash Flow | -$9,918 | -$13,779 | -$16,580 | -$13,527 |